Analysis of risk factors for the efficacy of tirofiban in the treatment of acute ischemic stroke

Objective To analyse the risk factors for tirofiban efficacy in the early treatment of acute ischemic stroke.Methods The clinical data of 204 patients with acute ischemic stroke treated with tirofiban were retrospectively analysed. The early efficacy of tirofiban was assessed by a ≥ 4-point decline in the National Institutes of Health Stroke Scale (NIHSS) score or via the complete disappearance of neurological deficits at the end of ischemic stroke treatment, and patients were divided into an effective groupand an ineffective group. Univariate and multivariate logistic regression analyses were used to compare the differences in clinical data between the two groups.Results Multivariate logistic regression analysis showed that heavy drinking (OR 0.477, 95% CI 0.249–0.899, P = 0.023), elevated total cholesterol (OR 0.331, 95% CI 0.141–0.734, P = 0.008), NIHSS score at initiation of treatment (OR 1.130, 95% CI 1.026–1.253, P = 0.016) and time from onset to treatment (OR 0.839, 95% CI 0.700–0.979, P = 0.038) were independent risk factors affecting the early efficacy of tirofiban.Conclusion The early curative effect of tirofiban in acute ischemic stroke patients with a heavy drinking history and elevated total cholesterol was poor. In patients with acute ischemic stroke, the higher the NIHSS score was within a certain range (8 < NIHSS ≤15 and the Org 10,172 Trial in the Treatment of Acute Stroke (TOAST) belongs to small-artery occlusion lacunar) at the initiation of treatment and the shorter the time from onset to treatment, the better the early curative effect was.